Trial Profile
A Prospective, Randomised, Double Blind, Placebo-Controlled Study to Assess the Efficacy of a Trivalent (A/New Caledonia/20/99, A/Panama/2007/99, B/Jiangsu/10/20) DNA Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) Against a Controlled Influenza Virus Challenge
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2007
Price :
$35
*
At a glance
- Drugs Influenza virus DNA vaccine (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 30 Jan 2007 Status change from Recruiting to Completed.
- 30 Oct 2006 New trial record.